Tag
This study develops a high-content ex vivo assay of T cell dynamics to predict multiple myeloma patient response to bispecific T cell engager therapies, offering a novel functional biomarker for therapy stratification.
Talquetamab, alone or combined with teclistamab, shows promising efficacy in treating relapsed/refractory multiple myeloma, including extramedullary disease, though high-grade adverse events are common but manageable.
The TRIMM-2 study reveals that talquetamab plus daratumumab yields high response rates and durable disease control in relapsed/refractory multiple myeloma with manageable safety, offering a novel combination strategy for heavily pretreated
